The half-life distinction
CJC-1295 Ipamorelin: DAC vs No-DAC Explained
One name, two very different molecules — a multi-day albumin-bound peptide and a half-hour pulse. Getting this right changes what every protocol claim means.
The gist
The phrase CJC-1295 Ipamorelin hides a fork in the cjc 1295 dac question. "CJC-1295" comes in two forms, and they behave nothing alike. The with-DAC form carries a small chemical handle — the Drug Affinity Complex (DAC) — that latches onto albumin, a protein in your blood, and rides along with it for days. The no-DAC form, called Mod GRF (1-29), has no handle and is gone in about half an hour. So when a write-up says "CJC-1295 lasts a week" and another says "CJC-1295 is short-acting," both can be right — they are describing different molecules. This page explains the chemistry behind the split and why it matters for reading any CJC-1295 Ipamorelin protocol. No doses, no advice.
With DAC: the multi-day albumin-bound form
The with-DAC version is what makes CJC-1295 unusual among GHRH analogues. It carries an N-epsilon-maleimidopropionamide-lysine — a maleimide handle — that covalently bonds to the Cys34 thiol of serum albumin shortly after injection [5]. Tethered to that long-lived carrier protein, the peptide resists clearance and keeps signalling the pituitary for days. In healthy adults, a single subcutaneous dose raised GH 2- to 10-fold for six or more days and IGF-1 for nine to eleven days, with IGF-1 elevated up to 28 days after multiple doses [1]. In rats, the bioconjugate produced about a 4-fold increase in GH area-under-curve over two hours versus unmodified hGRF(1-29), with albumin-bound peptide detectable beyond 72 hours [5]. The DAC, in short, converts a fragile minutes-long hormone signal into a multi-day one.
Mod grf 1-29: the no-DAC short-pulse form
Mod GRF (1-29) is CJC-1295 without the DAC — the same modified 29-amino-acid GHRH fragment, but with no albumin handle. The four amino-acid substitutions that make it "modified" improve stability against the enzyme DPP-IV (dipeptidyl peptidase-IV) and lengthen its action modestly versus the raw natural fragment, but without the albumin tether it still clears on the order of minutes to about 30 minutes. The practical consequence: Mod GRF (1-29) delivers a short, sharp GHRH pulse rather than a sustained background. In a stack, that short pulse is closer in timescale to ipamorelin's own brief action — which is part of why some research protocols favor the no-DAC form when the goal is to mimic the body's natural pulsatile GH pattern rather than flood the axis continuously.
Why the distinction changes the whole picture
Pairing a multi-day agent (with-DAC) with a short-acting one (ipamorelin) means the two are out of phase: the GHRH signal is always on while the ghrelin-arm pulse comes and goes. Pairing two short agents (Mod GRF 1-29 + ipamorelin) produces brief, overlapping pulses instead. These are genuinely different exposure profiles, and the safety reasoning differs too — a continuous multi-day GHRH drive from the DAC version is not the same exposure the acute synergy studies measured [3]. Because no controlled trial has tested either combination as a fixed blend, the net GH exposure of any given protocol is uncharacterized. That is the honest bottom line, and it is why this review keeps the two CJC-1295 forms strictly apart everywhere they appear.
A note on safety across both forms
Whichever form is used, the cautions on CJC-1295 Ipamorelin effects apply, because both ultimately raise the GH/IGF-1 signal. The class review of GH secretagogues flags increased blood glucose from reduced insulin sensitivity as the chief metabolic concern and notes that long-term safety data are lacking [6]. The with-DAC form's multi-day elevation [1] simply means that drive is sustained rather than transient — relevant to the fluid-retention and glucose considerations. None of this is observed harm from a blend trial; it is mechanism-grounded reasoning, and there is no FDA approval for either form.